A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
The purpose of this study is to investigate the efficacy and safety of HIPEC plus apatinib and S-1 in the conversion therapy of gastric cancer with positive exfoliative cancer cells
Gastric Cancer
DRUG: paclitaxel apatinib S-1
R0-resection rate, There was no residual by the microscope, within 3 weeks after surgery|Conversion to negative rate, Exfoliative cytology positive gastric cancer conversion to negative rate, within 3 weeks after surgery
Overall survival (OS), Baseline to measured date of death from any cause, 5years|Progression free survival (PFS), Baseline to measured date of progression or death from any cause, 5years|Adverse events, Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.The number of Participants with adverse events will be recorded at each treatment visit, 5 years
The purpose of this study is to investigate the efficacy and safety of HIPEC plus apatinib and S-1 in the conversion therapy of gastric cancer with positive exfoliative cancer cells